Investigational drug · Phase 3
SKB264
Also called: MK-2870, Sacituzumab Tirumotecan, Sac-TMT, SKB264 MK-2870
Not approved by FDA. In 53 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
53
51 still active
All registered trials
77
Any phase or sponsor naming "SKB264"
First trial start
2020
Feb 28, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB264", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Non-small Cell Lung Cancer (NSCLC)
- Triple Negative Breast Neoplasms
- Advanced Solid Tumors
- Malignant Neoplasm
- Lung Neoplasm Malignant
- Endometrial Cancer
- Bladder Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Cervical cancer · Endometrial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB264" as an intervention, largest first.
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruiting
Klus Pharma Inc.Industry
NCT04152499 · 1,410 participants · Start Feb 28, 2020 · Primary completion Nov 30, 2025
Drug: SKB264 · For: Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma and 7 more
Sites: Glendale, California; Los Angeles, California; Sarasota, Florida · 109 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06952504 · 1,123 participants (planned) · Start May 22, 2025 · Primary completion May 24, 2032
Drug: Pembrolizumab; Carboplatin and 4 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Irvine, California · 272 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216703 · 1,023 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 29, 2031
Drug: Pembrolizumab; Sacituzumab Tirumotecan and 5 more · For: Cervical Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Irvine, California · 189 sites in all
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07318558 · 900 participants (planned) · Start Feb 16, 2026 · Primary completion Feb 25, 2033
Drug: Sacituzumab tirumotecan; Bevacizumab and 1 more · For: Ovarian Neoplasms; Ovarian Cancer
Sites: Birmingham, Alabama; La Jolla, California; Newport Beach, California · 178 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06312137 · 780 participants (planned) · Start Apr 3, 2024 · Primary completion Feb 21, 2034
Drug: Sacituzumab tirumotecan; Pembrolizumab and 6 more · For: Non Small Cell Lung Cancer
Sites: Little Rock, Arkansas; Springdale, Arkansas; Beverly Hills, California · 271 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06824467 · 770 participants (planned) · Start Apr 9, 2025 · Primary completion Apr 27, 2029
Drug: Sacituzumab tirumotecan; Bevacizumab and 5 more · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Duarte, California · 203 sites in all
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06132958 · 710 participants (planned) · Start Dec 6, 2023 · Primary completion Jan 10, 2028
Drug: Sacituzumab tirumotecan; Doxorubicin and 3 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 242 sites in all
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06459180 · 686 participants (planned) · Start Jul 24, 2024 · Primary completion Jun 15, 2028
Drug: Sacituzumab Tirumotecan; Pemetrexed and 5 more · For: Cervical Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 240 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06170788 · 614 participants (planned) · Start Dec 15, 2023 · Primary completion Jan 25, 2028
Drug: Sacituzumab tirumotecan; Pembrolizumab and 1 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Phoenix, Arizona; Burbank, California; Grand Junction, Colorado · 220 sites in all
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07419295 · 590 participants (planned) · Start Apr 23, 2026 · Primary completion Jul 27, 2029
Drug: Sacituzumab tirumotecan; Vinflunine and 4 more · For: Bladder Cancer
Sites: Newport Beach, California; Aurora, Colorado; Highlands Ranch, Colorado · 117 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01.
Xu B, Yin Y, Fan Y, et al. · Ann Oncol 2026
- TROP-2-Directed ADC Could Be New Standard for Some NSCLCs.
· Cancer Discov 2026
- Sacituzumab tirumotecan-pembrolizumab has efficacy in PD-L1-negative NSCLC.
Romero D · Nat Rev Clin Oncol 2026
- TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome.
Stanbery L, Craig D, Rager L, et al. · Expert Rev Anticancer Ther 2026
- An evaluation of sacituzumab tirumotecan for the treatment of NSCLC.
Wang J, Zhou Y, Wu L · Expert Opin Biol Ther 2026
- Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
Lorusso D, Martin-Babau J, Backes F, et al. · Lancet 2026
Also in development for Non-Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.